Drug Discovery, Delivery and Experimental Therapeutics Program

药物发现、给药和实验治疗：摘要 药物发现、交付和实验治疗(D3ET)研究计划集成了广泛的 有助于发现新的癌症治疗药物的一系列研究领域 有效给药的途径；治疗和治疗的药物产品和诊断的开发 癌症的预防；以及在假设驱动的实验中对这些医学创新的评估 治疗试验。D3ET围绕三个中心、高度整合的科学主题组织：1)药物 发现和交付；2)药物和诊断发展；以及3)新癌症治疗方法的评估 实验治疗试验中的策略。D3ET有62名成员，包括36名正式成员和26名助理成员 会员。成员包括一系列高级和早期调查人员，其中包括27名教授，13名 副教授和20名助理教授以及两名关键的共享资源人员。D3ET成员 来自儿童慈善会(CM)、堪萨斯大学劳伦斯分校(KU-L)、 和堪萨斯城的堪萨斯大学医学中心(KUMC)，为 学科多样性和团队科学。 在报告期间(2020财年)，85%的计划成员与癌症相关，由外部资助 研究经费。从2016-2020年，D3ET计划实现了强大且不断增长的癌症重点研究 公文包。D3ET成员在过去五年中增加了一倍的资金(增加了1500万美元)，其中有700万美元 增加的资金包括同行审查资金和800万美元的非同行审查资金，以及近 NCI赞助的直接资金翻了一番。D3ET成功地推进了KU发明的五种癌症 治疗药物(见表4)，用于过去四年的临床试验。D3ET程序已经制作了 在发表其研究成果方面取得了实质性进展，增加了方案内(33%)和方案间 程序性协作(21%)。2016至2020年间，D3ET成员发布了902份与癌症相关的报告 出版物(每个成员平均有14.5份出版物)，包括142份在期刊上发表的影响较大的出版物 影响因子≥为10.0(16%)。D3ET由John A.Taylor，医学博士，硕士(KUMC)，Priyanka Sharma， 医学博士(KUMC)和丹·A·迪克森博士(KU-L)，他们在药物发现方面带来了互补的科学专业知识， 发展和实验疗法，以及良好的指导记录。这种高度互动性 领导力团队每两周与药学博士(KUMC)翻译副主任Scott Weir会面 研究，以确保与更广泛的癌症中心目标和倡议无缝结合。

DRUG DISCOVERY, DELIVERY AND EXPERIMENTAL THERAPEUTICS: ABSTRACT The Drug Discovery, Delivery and Experimental Therapeutics (D3ET) research program integrates a broad range of research areas that contribute to the discovery of new cancer therapeutic agents as well as novel approaches to effective drug delivery; the development of drug products and diagnostics for the treatment and prevention of cancer; and the evaluation of these medical innovations in hypothesis-driven experimental therapeutics trials. D3ET is organized around three central, highly integrated scientific themes: 1) Drug Discovery and Delivery; 2) Drug and Diagnostic Development; and 3) Evaluation of New Cancer Treatment Strategies in Experimental Therapeutic Trials. D3ET has 62 members, including 36 full and 26 associate members. Membership reflects a range of senior and early stage investigators with 27 Professors, 13 Associate Professors and 20 Assistant Professors and two key shared resource personnel. D3ET members are drawn from 25 departments across Children’s Mercy (CM), the University of Kansas in Lawrence (KU-L), and the University of Kansas Medical Center in Kansas City (KUMC), providing a rich environment for discipline diversity and team science. During the reporting period (CY20), 85% of program members have cancer relevant, externally funded research grants. From 2016-2020, the D3ET program achieved a strong and growing cancer-focused research portfolio. D3ET members have doubled funding (increase of $15M) over the past five years with $7M of this increase comprised of peer-reviewed funding and $8M of non-peer reviewed funding, along with a near doubling of NCI-sponsored direct funding. D3ET has successfully advanced five KU-invented cancer therapeutic agents (See Table 4), to clinical trials over the past four years. The D3ET program has made substantial progress in publishing its research and increasing intra-programmatic (33%) and inter- programmatic (21%) collaborations. Between 2016 and 2020, D3ET members published 902 cancer-relevant publications (an average of 14.5 publications per member), including 142 high-impact publications in journals with impact factors ≥ 10.0 (16%). D3ET is jointly led by John A. Taylor, MD, MS (KUMC), Priyanka Sharma, MD (KUMC), and Dan A. Dixon, PhD (KU-L), who bring complementary scientific expertise in drug discovery, development and experimental therapeutics and strong track records of mentorship. This highly interactive leadership team meets biweekly with Scott Weir, PharmD, PhD (KUMC), Associate Director for Translational Research, to ensure seamless integration with broader cancer center goals and initiatives.